hotspot -WSS

hotspot

author：entertainment 2025-09-29 19:58:44 - browse：354

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Ambulance rides for just $100? Advisers want major billing fixes

knowledge

WSS

UCSF medical school apologizes for unethical prisoner experiments

Medicare bonuses could stop drug shortages under Senate plan

A clever new way to fix Medicaid and graduate medical education

Medicare bonuses could stop drug shortages under Senate plan

Inaction leaves children at risk from dangerous chemotherapy drug

Diversify hospital leadership teams to protect BIPOC patient health

Wikipedia

hotspot

Wikipedia

Heart attack and stroke risk calculators need revising

Ambulance rides for just $100? Advisers want major billing fixes

United colonoscopy coverage change 'may cost lives,' doctors say

Abortion clinic in Cancun will cater to Americans

In Memoriam: Notable people who died in 2023

Inaction leaves children at risk from dangerous chemotherapy drug

The cancer drug shortage isn’t new — and neither are the solutions

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Novavax promises a turnaround & Lilly roils the obesity market

Free speech concerns arise in wake of journal editor Eisen's firing

hotspot

Ambulance rides for just $100? Advisers want major billing fixes

The Sacklers, horror, and ‘The Fall of the House of Usher’

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

FDA sets aggressive timeline for overhauling inspection procedures

Excited delirium, Elijah McClain, and emergency physicians

There's an unseen cost to disruptive road

focus

hotspot

knowledge

explore